Neurodegenerative biotech Vyant warns of potential wind-down

Kyle LaHucik

Senior Reporter

The CEO and chief scientific officer of Vyant Bio are out the door as the little-known but publicly-listed neurodegenerative biotech searches for an exit or …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Neurodegenerative biotech Vyant warns of potential wind-down

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Senior AstraZeneca exec detained in China amid wider investigation

Pfizer to invest $1B in China over next five years — reports

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Stephen Squinto's JPM life sciences team is raising a new fund for later-stage companies

Avid Bioservices to be sold to private equity firms for $1.1B

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Neu­rode­gen­er­a­tive biotech Vyant warns of po­ten­tial wind-down

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Stephen Squin­to's JPM life sci­ences team is rais­ing a new fund for lat­er-stage com­pa­nies

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Neurodegenerative biotech Vyant warns of potential wind-down

Senior AstraZeneca exec detained in China amid wider investigation

Pfizer to invest $1B in China over next five years — reports

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Stephen Squinto's JPM life sciences team is raising a new fund for later-stage companies

Avid Bioservices to be sold to private equity firms for $1.1B

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks